Technical Analysis for 0RC6 - Pharma Mar SAU
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 28.80 | -1.67% | -0.49 |
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
20 DMA Resistance | Bearish | 0.00% | |
200 DMA Resistance | Bearish | 0.00% | |
50 DMA Resistance | Bearish | 0.00% | |
New 52 Week Closing Low | Bearish | 0.00% | |
Shooting Star Candlestick | Bearish | 0.00% | |
Lizard Bearish | Bearish Day Trade Setup | 0.00% | |
Expansion Breakdown | Bearish Swing Setup | 0.00% | |
Expansion Pivot Sell Setup | Bearish Swing Setup | 0.00% | |
Reversal New Lows Setup | Bearish Swing Setup | 0.00% | |
Slingshot Bullish | Bullish Swing Setup | 0.00% |
Get this analysis on your stocks daily!
Pharma Mar SAU Description
Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, Italy, Germany, Ireland, France, rest of EU, the United States, and internationally. The company operates through Oncology and RNA interference segments. It develops and commercializes Yondelis for the treatment of soft tissue sarcoma and for ovarian cancer; Aplidin for treating R/R multiple myeloma; and Zepzelca for treating patients with small cell lung cancer. The company also develops PM14, which is in phase II clinical trials for the treatment of solid tumors, as well as in Phase I clinical trial for the treatment of soft tissue sarcoma and prostate cancer; PM534 that is Phase I clinical trial for treating solid tumors; Tivanisiran, which is in Phase III clinical trial for the treatment of dry eye disease; and SYL1801 that is in phase II clinical trial for treating macular degeneration. In addition, it engages in the development, production, and sale of products with therapeutic activity based on reducing or silencing gene expression. The company was incorporated in 1986 and is based in Madrid, Spain.
Classification
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 64.34 |
52 Week Low | 28.8 |
Average Volume | 2,030 |
200-Day Moving Average | 34.88 |
50-Day Moving Average | 37.97 |
20-Day Moving Average | 34.57 |
10-Day Moving Average | 29.86 |
Average True Range | 19.87 |
RSI (14) | 11.50 |
ADX | 25.95 |
+DI | 2.70 |
-DI | 2.34 |
Chandelier Exit (Long, 3 ATRs) | 0.64 |
Chandelier Exit (Short, 3 ATRs) | 88.40 |
Upper Bollinger Bands | 44.74 |
Lower Bollinger Band | 24.39 |
Percent B (%b) | 0.22 |
BandWidth | 58.87 |
MACD Line | -2.89 |
MACD Signal Line | -2.39 |
MACD Histogram | -0.4999 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 75.96 | ||||
Resistance 3 (R3) | 81.20 | 70.72 | 68.10 | ||
Resistance 2 (R2) | 70.72 | 58.71 | 68.10 | 65.48 | |
Resistance 1 (R1) | 49.76 | 51.29 | 44.52 | 44.52 | 62.86 |
Pivot Point | 39.28 | 39.28 | 36.66 | 36.66 | 39.28 |
Support 1 (S1) | 18.32 | 27.27 | 13.08 | 13.08 | -5.26 |
Support 2 (S2) | 7.84 | 19.85 | 5.22 | -7.88 | |
Support 3 (S3) | -13.12 | 7.84 | -10.50 | ||
Support 4 (S4) | -18.36 |